What Yupelri Treats: Main Uses and Benefits

Managing Chronic Obstructive Pulmonary Disease (COPD)

Yupelri is commonly used for foundational maintenance treatment in adult patients with Chronic Obstructive Pulmonary Disease (COPD). This medication is applied across domains where additional symptomatic support is needed to help manage symptoms related to physical discomfort and chronic airflow limitation. The medication is used to help ease disruptive symptom clusters of COPD, primarily persistent breathlessness, wheezing, and chest tightness. The purpose is to offer supportive symptomatic relief for chronic airflow limitation.

Providing Support for Breathing Symptoms and Symptom Relief

The key benefit of this long-term therapy is the delivery of durable symptomatic support to the airways. This stability generally assists with maintaining functional stability and supports general well-being during symptomatic phases, contributing to easing the overall symptom load. It helps patients cope more steadily with chronic symptoms and may help lessen the impact of exertional breathing difficulty on routine activities.

“This therapy may be part of symptomatic management by providing continuous support to the airways, which is relevant for managing chronic symptoms and supports general well-being during symptomatic periods.”

Regulatory References

1. NIH MedlinePlus overview

Eligibility Scope

The eligibility for Yupelri (Revefenacin) is strictly defined by regulatory authorities and applies only to adult patients (18 years of age and older) who require maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD).

Contraindicated Populations and Restrictions

Contraindications (Prohibited Use):

• Patients with a known hypersensitivity to revefenacin or any component of the product.
• Individuals experiencing acutely deteriorating COPD or those who require relief from acute bronchospasm; the medicine is not approved as rescue therapy.

Restricted or Conditional Use:

• Hepatic Impairment: Use is not recommended in patients with any degree of liver impairment, as safety has not been fully established.
• Glaucoma and Urinary Issues: Caution is advised for patients with narrow-angle glaucoma or conditions leading to urinary retention, such as prostatic hyperplasia or bladder-neck obstruction.
• Pediatric Use: The medicine is not approved for use, and its safety and efficacy have not been established in pediatric patients (under 18 years of age).

Reproductive Status:

• Use during pregnancy or lactation is conditional due to limited human data, and caution is advised.

Interactions with other medicines and products

This section outlines the official interaction information for Yupelri (revefenacin) as documented in government regulatory sources, strictly describing documented interaction patterns and constraints.

Interaction Scope

Official Interaction Statements

• Co-administration with other anticholinergic-containing medicines must be avoided due to the potential for additive pharmacodynamic effects as stated in the label.
• Coadministration with OATP1B1 and OATP1B3 inhibitors is not recommended because these substances cause a documented increase in the systemic exposure of the drug's active metabolite.
• Neither the drug nor its active metabolite is documented as an inhibitor or inducer of any major CYP450 isoforms, indicating no anticipated metabolic interaction via these enzymes.
• The product must not be mixed with any other drug in the nebulizer, as the safety and compatibility for this procedural co-administration have not been established by regulators.

Connection to the Overall Interaction Profile

The regulatory profile defines the interaction structure around two primary constraints: the restriction against using other anticholinergic medicines based on additive pharmacodynamic effects, and the non-recommendation of use with specific transporter inhibitors due to altered systemic drug exposure. This profile confirms no anticipated interaction via major metabolic CYP450 enzymes but mandates a procedural constraint against mixing the solution with any other medication in the nebulizer.

Revefenacin acts as a competitive antagonist against the M3 muscarinic receptors found on the airway smooth muscle. This molecular interaction blocks the signal transmission of the parasympathetic nervous system by preventing the binding of the endogenous neurotransmitter acetylcholine ( ACh). The antagonism inhibits the subsequent intracellular cascade—the G q protein signaling pathway—which normally leads to the mobilization of calcium ions ( Ca^2+) and muscle contraction. The molecule exhibits slow dissociation kinetics from the M3 receptor, which facilitates the prolonged prevention of muscle contraction. This continuous inhibition results in prolonged bronchodilation and the sustained relaxation of the bronchial smooth muscle. The mechanism is a consistent modulation of M3 activity, primarily regulating the proportion of airway constriction mediated by muscle tone. Its physiological effect is constrained by the proportion of muscle-tone-driven restriction and is ineffective against non-reversible structural changes.

Official Administration Guidelines for Yupelri

Yupelri (revefenacin) is a long-acting inhaled medication intended exclusively for the long-term maintenance treatment of chronic airflow obstruction. Its usage is highly specific and it is not designated for the relief of acute or sudden breathing symptoms.

Procedural Constraints and Special Populations

Preparation and Handling: The single-use vial must be opened and its content transferred to the nebulizer cup immediately before use. The solution is supplied ready-to-use and must not be mixed with any other nebulized solutions. The vial and any residual contents must be discarded immediately after the treatment is concluded.

Missed-Dose Protocol: If administration is missed, the dose should be taken as soon as feasible. Conversely, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Doses must never be doubled.

Dose Adjustments: Dosage adjustment is not necessary for older adult patients or those with renal impairment. However, the use of Yupelri is not recommended in patients presenting with any degree of hepatic impairment.

Research Evidence / Overview of Studies for Yupelri

Evidence for Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Research examined the use of Yupelri (revefenacin) as a daily maintenance treatment for adults living with chronic airflow obstruction, which is a key characteristic of COPD. The evidence relies heavily on short-term, high-quality clinical studies known as Randomized Controlled Trials (RCTs). These short-term RCTs, typically lasting 12 weeks, were applied in studies examining patient-reported experiences and focused on measuring changes in pulmonary function in adults with moderate to very severe COPD.

The main objective of these studies was to monitor a specific measure of lung capacity, known as Trough Forced Expiratory Volume in 1 second ( FEV1), to measure the pulmonary function observed at the end of the 24-hour dosing period. Research also explored patient-reported outcomes describing perceived discomfort and overall health status using standardized questionnaires. These findings describe patterns observed in the studies regarding measured pulmonary function.

How Revefenacin was Studied: Comparing to Placebo

The primary evidence base for revefenacin utilized multiple 12-week trials where participants were randomly assigned to receive either the nebulized medication or a placebo (a non-active substance). This approach was chosen to establish whether the medication's effects were distinct from the effects of receiving no treatment at all. Studies reported measurements of FEV1 between the group that received the medication and the group that received placebo at the end of the short study period. These study results reflect the specific conditions under which they were conducted and help contextualize how patients reported their experience over the duration of the trials.

Long-Term Studies and Durability of Response

Beyond the 12-week core studies, one longer trial, which lasted 52 weeks (one full year), was observed in a randomized, but open-label, setting. This evidence contributes to the broader evidence landscape but long-term effects are not fully established based on a single, primary efficacy trial extending beyond 12 weeks.

What Remains Uncertain in the Research

While replicate, high-quality short-term RCTs provide the primary evidence base for the lung function endpoint, several areas require further research. Furthermore, the evidence related to the rate of COPD exacerbations (acute or disruptive episodes) was observed in some studies as a secondary outcome. The limited scope of this research means the pattern observed may not fully characterize the outcome. Lastly, because the main trials excluded patients with certain complex medical histories, data for certain groups remain insufficient to fully characterize the medication’s role across the entire real-world COPD population.

Key Studies & References

1. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials (Studies 0126 and 0127)

Common questions about Yupelri (FAQ)

Q: Is Yupelri the same kind of medicine as Spiriva or Trelegy?

A: Yupelri is classified by official product information as a Long-Acting Muscarinic Antagonist (LAMA), which is a type of bronchodilator. Other medicines for COPD, such as Spiriva, also belong to the LAMA drug class. Trelegy, however, is a combination medicine containing a LAMA, a LABA, and an inhaled corticosteroid.

Q: What is the main difference between Yupelri and other inhalers for COPD?

A: According to the official product information, a key distinguishing feature of this medicine is its formulation as an aqueous inhalation solution. It is designed exclusively for delivery using a standard jet nebulizer. Many other bronchodilator medicines use different types of inhaler devices, such as dry powder inhalers or metered-dose inhalers.

Q: Can Yupelri be used for asthma, even if it's for COPD?

A: Regulatory documents state that Yupelri is strictly indicated only for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). Use for asthma or any other lung condition is not included in the medication's approved labeling.

Q: How long does the effect of a Yupelri dose last?

A: Yupelri is classified as a long-acting medicine and is administered once daily. Studies and official information indicate that the bronchodilator effect is sustained for up to 24 hours.

Q: Is it safe to use other breathing treatments (nebulizers) on the same day as Yupelri?

A: Official regulatory information states that the Yupelri solution must not be mixed with any other medicine in the nebulizer cup. If other breathing treatments are needed, it is important to administer them separately.

Q: Is it normal if my eyes sting or feel irritated after using the nebulizer?

A: The prescribing information notes that symptoms associated with worsening narrow-angle glaucoma may include red eyes and eye pain or discomfort. If you experience these kinds of eye symptoms, or blurred vision, it is recommended that patients consult promptly with a healthcare professional.

Q: Can Yupelri be used by people who have glaucoma?

A: Official regulatory sources advise using this medicine with caution in patients diagnosed with narrow-angle glaucoma. This caution is in place because the medicine may potentially worsen the signs or symptoms of the condition.

Q: Can I use Yupelri if I have a history of prostate problems?

A: The prescribing information advises caution for patients who have a history of conditions like prostatic hyperplasia (enlarged prostate) or bladder-neck obstruction. This is due to the potential risk of new or worsened urinary retention.

Q: What are the signs of an allergic reaction to Yupelri?

A: Regulatory documents classify immediate hypersensitivity reactions as a serious safety concern. Signs may include skin reactions such as rash or hives, or more severe symptoms like swelling of the face, mouth, and tongue, and difficulty breathing or swallowing.

Q: Has Yupelri been studied in people with kidney or liver issues?

A: Regulatory documents note that no dosage adjustment is required for patients presenting with renal impairment (kidney issues). However, use of the medicine is not recommended in patients presenting with any degree of hepatic impairment (liver problems).

Q: Can I use Yupelri when I have a common cold or respiratory infection?

A: Official product information lists upper respiratory tract infection (common cold symptoms) and nasopharyngitis as commonly reported side effects. It is important to remember that this medicine is for maintenance treatment only, and not for acute, sudden breathing problems.

Q: What is the reported evidence for Yupelri's long-term effectiveness?

A: The main evidence supporting the medication’s efficacy relies on clinical trials lasting 12 weeks. While a longer, 52-week study was observed, the available regulatory information suggests that the long-term effects are not fully established based on the primary data set used for approval.

Q: How long does it take after a dose of Yupelri to start feeling a difference?

A: Clinical study results indicate the onset of action by measuring lung function. The median time to achieve a small, measurable increase in lung function ( FEV1) was reported as 30 minutes following the first dose.

Q: Can patients with heart issues like atrial fibrillation use Yupelri?

A: The prescribing information does not list heart conditions such as atrial fibrillation as a specific warning or contraindication. The label notes that no effect on the QT interval (a measure of heart rhythm) was observed in healthy individuals following a single dose.

Q: Can Yupelri cause dry mouth or throat?

A: Dry mouth is a known potential effect of the drug class (anticholinergics) to which this medicine belongs. However, it is not listed among the most frequently reported side effects in the regulatory prescribing information for this specific medicine.

Q: Does Yupelri contain steroids?

A: According to the official product description, the active ingredient is revefenacin, which is classified as a Long-Acting Muscarinic Antagonist (LAMA). The official list of solution ingredients does not include any corticosteroids (steroids).

Q: Do I need to change my nebulizer machine settings for Yupelri?

A: The official Instructions For Use state that the amount of medication delivered to the lungs can depend on factors including the type of nebulization system used and the compressor performance. The official Instructions For Use recommend consulting the manufacturer's instructions for the specific nebulizer system being used.

Q: Does Yupelri affect my ability to drive or operate machinery?

A: Regulatory documents indicate that the medicine may potentially cause visual changes, such as blurred vision. Regulatory documents recommend that patients use caution when driving or operating machinery until they are familiar with how the medicine affects them.

How to Store and Dispose of Yupelri?

The official guidelines for Yupelri (revefenacin) inhalation solution focus on maintaining product stability and ensuring safe handling.

Storage Requirements

Disposal Instructions

The product is intended for single use. Once the foil pouch is opened, the vial must be used right away, and any remaining solution in the opened vial must be discarded immediately after use. To dispose of expired or unused medication, consult a healthcare professional or pharmacist for instructions on proper disposal methods.